

```

Db      1 MKAAGLLGICARAMNSVRRASGGMTRRDP LANKYALVASTDGI GFALARRLAODGAAHV 60
OY      61 VSSKROONVDOAVATLOGEGLSVTGTCVCHGKADREERLYAVAVKHLGGIDILVSNAAVN 120
Db      61 VSSKROONVDOAVATLOGEGLSVTGTCVCHGKADREERLYAVAVKHLGGIDILVSNAAVN 120
OY      121 PFFGSIMDVTEEVWMDKTLIDINVKAPALMTKAVPEMEKRGSGSVIVSSIAAFSPSGFS 180
Db      121 PFFGSIMDVTEEVWMDKTLIDINVKAPALMTKAVPEMEKRGSGSVIVSSIAAFSPSGFS 180
OY      181 PYNVSKTALLGLTKTLAIELAPRNIRVNCIAPGLIKTSFRMLMDKKEESMKTLLRIR 240
Db      181 PYNVSKTALLGLTKTLAIELAPRNIRVNCIAPGLIKTSFRMLMDKKEESMKTLLRIR 240
OY      241 RLGEPEDCAGIVSFLCSEDSASTITGEIVVVGSGTSPRL 278
Db      241 RLGEPEDCAGIVSFLCSEDSASTITGEIVVVGSGTSPRL 278

```

RESULT 3

AAB93414
ID AAB93414 standard; Protein: 278 AA.

AC AAB93414;
XX
XX
XX 26-JUN-2001 (first entry)

DE Human protein sequence SEQ ID NO:12620.

KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.

XX Homo sapiens.

XX EPI074617-A2.

XX 07-FEB-2001.

XX 28-JUL-2000; 2000EP-0116126.

XX 29-JUN-1999; 99TP-0248036.

XX 27-AUG-1999; 99UP-0300233.

XX 11-JAN-2000; 2000JP-0118776.

XX 02-MAY-2000; 2000JP-0183767.

XX 09-JUN-2000; 2000JP-0241899.

XX (HELI-) HELIX RES INST.

XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

XX Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

XX WPI; 2001-318749/34.

XX Claim 8; SEQ ID 12620; 2537pp + CD ROM; English.

XX The present invention describes primer sets for synthesizing 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and

CC in gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92445 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.

XX Sequence 278 AA:

Query Match 99.7%; Score 1395; DB 22; Length 278;

Best Local Similarity 99.6%; Pred. No. 2e-131;

Matches 277; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 MKAAGLLGICARAMNSVRRASGGMTRRDP LANKYALVASTDGI GFALARRLAODGAAHV 60

Db 1 MKAAGLLGICARAMNSVRRASGGMTRRDP LANKYALVASTDGI GFALARRLAODGAAHV 60

OY 61 VSSKROONVDOAVATLOGEGLSVTGTCVCHGKADREERLYAVAVKHLGGIDILVSNAAVN 120

Db 61 VSSKROONVDOAVATLOGEGLSVTGTCVCHGKADREERLYAVAVKHLGGIDILVSNAAVN 120

OY 121 PFFGSIMDVTEEVWMDKTLIDINVKAPALMTKAVPEMEKRGSGSVIVSSIAAFSPSGFS 180

Db 121 PFFGSIMDVTEEVWMDKTLIDINVKAPALMTKAVPEMEKRGSGSVIVSSIAAFSPSGFS 180

OY 181 PYNVSKTALLGLTKTLAIELAPRNIRVNCIAPGLIKTSFRMLMDKKEESMKTLLRIR 240

Db 181 PYNVSKTALLGLTKTLAIELAPRNIRVNCIAPGLIKTSFRMLMDKKEESMKTLLRIR 240

OY 241 RLGEPEDCAGIVSFLCSEDSASTITGEIVVVGSGTSPRL 278

Db 241 RLGEPEDCAGIVSFLCSEDSASTITGEIVVVGSGTSPRL 278

RESULT 4

AAV68735
ID AAV68735 standard; Protein: 278 AA.

XX AAV68735;
XX
XX 05-MAY-2000 (first entry)

DE Short chain alcohol dehydrogenase-related molecule SCRM-1 protein.

XX Human; short chain alcohol dehydrogenase-related molecule;

XX SCAD-related molecule; SCRM-1; SCRM-2; metabolic regulator;

XX cell proliferation regulator; inflammation regulator;

XX atherosclerosis; bursitis; cirrhosis; hepatitis; AIDS;

XX Addison's disease; adult respiratory distress syndrome; allergy;

XX ankylosing spondylitis; cancer.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Modified-site 16

FT Modified-site 21

FT Modified-site 25

FT Modified-site 31

FT Region 33..45

FT Region 34..51

FT Binding-site 39..46

FT Modified-site /note= "AMP-binding domain"
 FT 62
 FT /note= "potential protein kinase C phosphorylation site"
 FT Modified-site 63
 FT /note= "potential protein kinase C phosphorylation site"
 FT Region 108..119
 FT /note= "glucose/ribitol dehydrogenase motif"
 FT Region 108..118
 FT /note= "SCAD motif"
 FT Region 108..119
 FT /note= "SCAD motif"
 FT Modified-site 125
 FT /note= "potential casein kinase II phosphorylation site"
 FT Region 156..172
 FT /note= "glucose/ribitol dehydrogenase motif"
 FT Region 162..193
 FT /note= "SCAD motif"
 FT Region 162..213
 FT /note= "SCAD signature sequence"
 FT Region 169..197
 FT /note= "SCAD family signature sequence"
 FT Region 182..201
 FT /note= "glucose/ribitol dehydrogenase motif"
 FT Domain 182..186
 FT /note= "canonical catalytic site of SCADs"
 FT Region 203..220
 FT /note= "glucose/ribitol dehydrogenase motif"
 FT Region 204..213
 FT /note= "SCAD motif"
 FT Modified-site 232
 FT /note= "potential casein kinase II phosphorylation site
 FT and potential protein kinase C phosphorylation
 FT site"
 FT Modified-site 236
 FT /note= "potential protein kinase C phosphorylation site"
 FT Region 238..258
 FT /note= "glucose/ribitol dehydrogenase motif"
 FT
 PN WO200004135-A2.
 PD 27-JAN-2000.
 PF 16-JUL-1999; 99WO-US16164.
 XX
 PR 16-JUL-1998; 98US-0116750.
 PR 16-JUL-1998; 98US-0160074.
 XX
 PA (INCYTE PHARM INC.
 PI Bandman O, Tang YT, Corley NC, Azimzai Y, Baughn MR;
 XX WPI: 2000-171266/15.
 DR N-PSDB; AA246080.
 XX
 PT New short chain alcohol dehydrogenase polypeptides useful for
 PT diagnosis, treatment and prevention of cell proliferative disorders
 PT such as atherosclerosis, cirrhosis and cancers of various tissues
 XX
 PS Claim 1, Fig 1A-D, 78pp; English.
 CC
 CC The present sequence represents a human short chain alcohol dehydrogenase
 CC (SCAD)-related molecule designated SCRM-1. The specification also
 CC describes SCRM-2. SCRM proteins are metabolic, cell proliferation and
 CC inflammation regulators. The SCRM polynucleotides and polypeptides are
 CC used for treating or preventing a cell proliferative or immune disorder
 CC in humans. Cell proliferative disorders include arteriosclerosis,
 CC atherosclerosis, bursitis, cirrhosis, and hepatitis. Immune disorders
 CC include AIDS, Addison's disease, adult respiratory distress syndrome,
 CC allergies, ankylosing spondylitis, and amyloidosis. The vectors,
 CC agonists, antagonists, antibodies and complementary sequences are also
 CC used for treating the above conditions. The polynucleotides and
 CC polypeptides are also used for treating cancers of various tissues
 CC such as adrenal gland, bladder, bone, bone marrow, and brain.

XX Sequence 278 AA;
 SQ
 Query Match 94.9%; Score 1327; DB 21; Length 278;
 Best Local Similarity 96.4%; Pred. No. 1.3e-124;
 Matches 268; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
 QY 1 MHKAGLGLCARVNSVYRMASGATRRDPLANKYALVTASTDGIHAIARRIADGAAHV 60
 DB 1 MHMARRILGLCAARKSVYRMASGATRRDPLNNKALVTASTDGIHAIARRIADGAAHV 60
 QY 61 VSSRKOQNVDOAVATLQGGGLSVTGCHVKAKADRRRLVAVNKIHGGIDILVNAHV 120
 DB 61 VSSRKOQNVDOAVATLQGGGLSVTGCHVKAKADRRRLVAVNKIHGGIDILVNAHV 120
 QY 121 PEEGSDIVTEEYWDKTLIDINKAPALMTKAVYEMKRGSGSVTVSSIAFSPSPGS 180
 DB 121 PEEGSDIVTEEYWDKTLIDINKAPALMTKAVYEMKRGSGSVTVSSIAFSPSPGS 180
 QY 181 PYNVSKTALLGLAKTALIELAPRNIRVNCIAPGLIKTSFSRMLMDKKEESMKETLRIR 240
 DB 181 PYNVSKTALLGLAKTALIELAPRNIRVNCIAPGLIKTSFSRMLMDKKEESMKETLRIR 240
 QY 241 RLGEPEDCAGIVSFLCEDASVITGETVYVGGGPSRL 278
 DB 241 RLGEPEDCAGIVSFLCEDASVITGETVYVGGGPSRL 278
 RESULT 5
 AAU30722
 ID AAU30722 standard; Protein; 477 AA.
 XX
 AC AAU30722;
 XX
 DT 18-DEC-2001 (first entry)
 XX
 DE Novel human secreted protein #1213.
 XX
 KW Human; vaccination; gene therapy; nutritional supplement;
 KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
 OS Homo sapiens.
 XX
 PN WO200179449-A2.
 PD 25-OCT-2001.
 XX
 PF 16-APR-2001; 2001WO-US08656.
 XX
 PR 18-APR-2000; 2000US-0552929.
 PR 26-JAN-2001; 2001US-0770160.
 XX
 PA (HYSEQ-) HYSEQ INC.
 PI Tang YT, Liu C, Dimanac RT;
 XX WPI: 2001-611725/70.
 DR
 XX
 PT Nucleic acids encoding a range of human polypeptides, useful in genetic
 PT vaccination, testing and therapy -
 XX
 PS Claim 20; Page 336; 765pp; English.
 CC
 CC The invention relates to novel human secreted polypeptides. The
 CC polypeptides and antibodies to the polypeptides are useful for
 CC determining the presence of or predisposition to a disease associated
 CC with altered levels of polypeptide. The polypeptides are also useful for
 CC identifying agents (agonists and antagonists) that bind to them. Cells
 CC expressing the proteins are useful for identifying a therapeutic agent
 CC for use in treatment of a pathology related to aberrant expression or
 CC physiological interactions of the polypeptides. Vectors comprising
 CC the nucleic acids encoding the polypeptides and cells genetically